- $148.58m
- $194.70m
- $149.16m
Neuronetics Inc expected to post a loss of 25 cents a share - Earnings Preview
Neuronetics Inc expected to post a loss of 25 cents a share - Earnings Preview
Brief: Neuronetics Provides Business Update And Issues 2025 Guidance
Neuronetics Inc expected to post a loss of 25 cents a share - Earnings Preview
Brief: Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Brief: Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
U.S. RESEARCH ROUNDUP- AMN Healthcare Services, Chart Industries, Home Depot
Neuronetics Inc reports results for the quarter ended September 30 - Earnings Summary
Neuronetics Inc expected to post a loss of 23 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Revance, B Riley, Neuronetics
Neuronetics tanks on Q2 net loss, acquisition announcement
Brief: Neuronetics And Greenbrook TMS Announce Definitive Agreement To Merge
Neuronetics Inc expected to post a loss of 27 cents a share - Earnings Preview
Brief: Neuronetics Says Aetna Updated TMS Coverage To Include Adolescents Aged 15 And Older With MDD
Neuronetics Inc reports results for the quarter ended in March - Earnings Summary
Neuronetics Inc expected to post a loss of 31 cents a share - Earnings Preview
Brief: Neuronetics - Would Reduce Number Of Directors Serving On Board From Eight To Five Effective Immediately After 2024 Annual Meeting Of Stockholders
Brief: NeuroStar Advanced Therapy Receives FDA Clearance As First-Line Add-On Treatment For Adolescents With Depression
Brief: Neuronetics Announces 5-Year Exclusive Partnership With Transformations Care Network